Cancer Metabolism Based Therapeutics Market Poised for Rapid Growth Due to Increasing Focus on Targeting Cancer Metabolism
The global cancer metabolism based therapeutics market is poised to witness substantial growth in the coming years. Cancer metabolism based therapeutics target the altered metabolic pathways in cancer cells, depriving them of essential nutrients and energy required for rapid proliferation. Some of the key players in the market including Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, and Rafael pharmaceuticals have developed novel therapeutic strategies focusing on modulating cancer cell metabolism.
Cancer cells alter their basic metabolism to fuel uncontrolled growth and proliferation. Targeting altered cancer cell metabolism deprives tumor cells of essential nutrients and energy required for their survival and advancement. Some of the key advantages of cancer metabolism based therapeutics include improved efficacy and reduced drug resistance as compared to conventional chemotherapeutics. Further, targeting cancer cell metabolism poses minimal risks of toxicity to normal cells. The global need for more effective targeted cancer therapies with improved safety profiles is driving focus towards developing cancer metabolism based therapeutics.
The Global cancer metabolism based therapeutics market is estimated to be valued at US$ 210.2 Bn in 2024 and is expected to exhibit a CAGR of 95% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the cancer metabolism based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, and Rafael pharmaceuticals. Calithera Biosciences is developing inhibitors targeting glutaminase, an enzyme important for glutamine metabolism in cancer cells. Celgene Corporation has multiple pipeline assets targeting metabolic pathways in hematological and solid tumors.
There is high unmet need for effective targeted therapies in several cancer types where current treatments have limited efficacy. Targeting altered metabolic pathways in these cancers presents significant opportunities for development of novel therapeutics. Further, cancer metabolism based therapeutics allow opportunities for combination with immunotherapies to enhance therapeutic response.
Key players are also partnering and conducting clinical trials globally to expand access to innovative cancer metabolism based therapeutics. For instance, Agios Pharmaceutical has several ongoing trials evaluating its PKM2 inhibitor in solid tumors in collaboration with global pharma players. This is expected to boost the adoption of cancer metabolism based treatments worldwide over the coming decade.
Market Drivers:
Increasing research understanding the role of altered cancer metabolism in disease pathogenesis and progression is driving focus on developing novel targeted therapies. Strategies targeting metabolic vulnerabilities in cancer cells using small molecules or other modalities have shown promise in preclinical and early clinical studies. This is expected to boost research and development of cancer metabolism based therapeutics.
Market Restrain:
Developing drugs targeting cancer metabolism is technically challenging given complex interactions between metabolic pathways and other cellular processes. Further long term clinical outcomes data to establish survival benefits is still emerging for most pipeline assets. This poses risks and increases development costs, acting as a key restraint for widespread adoption of cancer metabolism based treatments.
Segment Analysis
The cancer metabolism based therapeutics market is broadly segmented into IDH inhibitors, CDK 4/6 inhibitors, PARP inhibitors, and PI3K inhibitors among others. IDH inhibitors sub-segment dominates the market currently due to the availability of FDA approved drugs of IDH inhibitors that target mutant IDH1 and IDH2 enzymes present in cancers like acute myeloid leukemia and glioma. The drugs inhibit the mutant IDH enzymes thereby limiting the production of oncometabolite 2-hydroxyglutarate (2-HG) that plays an important role in cancer progression.
Global Analysis
Regionally, North America accounts for the largest share in the cancer metabolism based therapeutics market owing to increasing prevalence of cancer, rising healthcare expenditure, and presence of key pharmaceutical companies in the region. However, Asia Pacific is anticipated to witness the highest growth during the forecast period majorly due to growing geriatric population, improving healthcare infrastructure, and increasing awareness about cancer treatment. Focus of pharmaceutical companies on emerging markets of Asia Pacific, increasing collaborative research, and introduction of low-cost biosimilars also contribute to the growth of regional market.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian